Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Nov 4, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that its Board of Directors declared a quarterly dividend of $0.21...
-
Oct 23, 2019
As a precautionary measure, Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has initiated a voluntary, worldwide product recall to the retail customer level of ranitidine (all pack...
-
Oct 15, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019. The Company will host a...
-
Oct 3, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced the relaunch of the AB rated generic equivalent of Transderm Scop® (scopolamine 1.5 mg). Annual market sales of Transderm Scop® and...
-
Sep 5, 2019- Expands U.S. OTC market and gastrointestinal category leadership positions
Perrigo Company plc (NYSE; TASE: PRGO) announced today that it has entered into a definitive agreement to acquire the branded OTC rights to Prevacid® from GlaxoSmithKline. Under the terms of the...
-
Aug 22, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will host one-on-one meetings at the Barclay's Global Consumer Staples...
-
Aug 21, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Nascobal® (Cyanocobalamin) Nasal Spray brought by Endo Pharmaceuticals Inc....
-
Aug 8, 2019
GAAP ("reported") net sales were $1.15 billion, reflecting a 3% decline versus the prior year period. Non-GAAP ("adjusted") net sales increased by approximately 1% excluding the unfavorable impact...
-
Aug 7, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading provider of "Quality Affordable Self-Care Products™", today announced that Jeffrey C. Smith, Managing Member, Chief Executive Officer, and Chief...
-
Jul 31, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that its Board of Directors declared a quarterly dividend of $0.21...
-
Jul 25, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its second quarter calendar year 2019 financial results on Thursday, August 8, 2019. The Company will host a conference...
-
Jul 8, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (NASDAQ: PETQ) for $185 million. Perrigo...
-
Jul 3, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced its product development partner received final approval from the U.S. Food and Drug Administration for its AB-rated Abbreviated New Drug...
-
Jul 2, 2019- Advances transformation to a consumer-focused, self-care company
Perrigo Company plc (NYSE; TASE: PRGO) today announced the successful completion of its acquisition of Ranir Global Holdings LLC ("Ranir"), the leading global store brand supplier of oral...
-
Jun 21, 2019
Dublin, Ireland and Allegan, MI – June 21, 2019 – Perrigo Company plc is issuing a voluntary nationwide recall of 35-ounce, 992-gram containers of Parent’s Choice Advantage Infant Formula...
-
May 21, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced its partner received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application (ANDA)...
-
May 9, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today is holding its Investor Day at the New York Stock Exchange in New York City, outlining its strategy to drive long-term growth and build shareholder...
-
May 9, 2019- All cash transaction valued at $750 million, or approximately $685 million inclusive of cash tax benefits on a present value basis
Perrigo Company plc (NYSE, TASE: PRGO) today announced that it has reached a definitive agreement to purchase privately-held Ranir Global Holdings LLC ("Ranir") in a transaction valued at $750...
-
May 8, 2019
GAAP ("reported") net sales were $1.2 billion, reflecting a 4% decline versus the prior year period, or down 1% excluding the unfavorable impact of currency. First quarter reported diluted...
-
May 8, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that it has reached a definitive agreement to sell its Animal Health business to PetIQ (NASDAQ: PETQ) in a transaction valued at $185...
-
May 1, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that it will release its first quarter calendar year 2019 financial results on May 8, 2019 after market close in the U.S. and will discuss...
-
Apr 26, 2019
Perrigo Company plc (NYSE; TASE: PRGO), today announced that the company's Board of Directors, consistent with its recently approved strategic plan to evolve to a consumer self-care company,...
-
Apr 18, 2019
Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of Quality, Affordable Self-Care Products™, today announced that it will hold its Investor Day on May 9 in New York City to...
-
Apr 4, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable, Self-Care Products™", today announced it has received tentative approval from the U.S. Food and Drug...
-
Apr 2, 2019
Perrigo Company plc (NYSE; TASE: PRGO) a leading global provider of "Quality, Affordable, Self-Care Products™", today announced that it has settled its Hatch-Waxman litigation relating to its...
-
Mar 20, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced that Ray Silcock will join the Company as Executive Vice President and Chief Financial Officer, effective March 25, 2019. Ray will lead the...
-
Mar 18, 2019
Perrigo Company plc (NYSE; TASE: PRGO) a leading global provider of "Quality, Affordable, Self-Care Products™" today announced it has received tentative approval from the U.S. Food and Drug...
-
Mar 5, 2019
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Endo Pharmaceuticals Inc. initiated patent litigation on March 1, 2019 in the United States District Court for the District of Delaware...
-
Feb 27, 2019
Full-year 2018 GAAP ("Reported") net sales of $4.7 billion, reflecting a 4% decline versus a year ago; Fourth quarter 2018 reported net sales of $1.2 billion, a 7% decline versus the prior year....
-
Feb 25, 2019- Committed to vigorously challenge the Notice of Amended Assessment; believes it is without merit and incorrect as a matter of law
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable, Self-Care Products™", today announced that its subsidiary, Perrigo Pharma International DAC ("Elan...
-
Feb 14, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that its Board of Directors declared a quarterly dividend of $0.19...
-
Feb 13, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that it has settled its Hatch-Waxman litigation relating to its...
-
Feb 13, 2019
Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that it will release its fourth quarter and calendar year 2018...
-
Feb 6, 2019
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application referencing...
-
Jan 29, 2019
Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of "Quality, Affordable Self-care Products™", today announced that the company expects to receive a milestone payment of $250...
-
Jan 14, 2019
Perrigo Company plc (NYSE, TASE: PRGO) today announced that James Dillard has been appointed Executive Vice President and Chief Scientific Officer. In this new role, Jim will be responsible for...
-
Dec 20, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that President and CEO Murray Kessler will present at the 37th Annual J.P. Morgan Global Healthcare Conference at 5:00 PM EST on Tuesday,...
-
Dec 10, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB-rated generic version of Topicort® (desoximetasone)Topical Spray 0.25%. Topicort® Topical Spray is indicated for the...
-
Nov 28, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Sernivo® (betamethasone dipropionate, 0.05%) Spray brought by Promius Pharma...
-
Nov 27, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has launched its AB rated abbreviated new drug application referencing Solaraze® Gel, 3% (diclofenac sodium gel, 3%). Solaraze® Gel, 3%...
-
Nov 26, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the first to file generic version of Ultravate® Lotion...
-
Nov 8, 2018
Realized third quarter 2018 GAAP ("reported") net sales of $1.1 billion, reported net loss of $68 million compared to a net income of $45 million last year and reported diluted loss per share of $0.49
-
Oct 31, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that its Board of Directors declared a quarterly dividend of $0.19 per share, payable on December 18, 2018 to shareholders of record on...
-
Oct 29, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Anacor Pharmaceuticals, Inc., initiated patent litigation on October 25, 2018 in the United States District Court for the District of...
-
Oct 26, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that Adapt Pharma Operations Limited, Adapt Pharma Inc., Adapt Pharma Ltd. and Opiant Pharmaceuticals initiated patent litigation on October...
-
Oct 25, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it will release its third quarter calendar year 2018 financial results on Thursday, November 8, 2018. The Company will host a conference...
-
Oct 15, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced the launch of an AB-rated generic version of Androgel® Topical Gel, 1.62% (20.25mg testosterone/1.25g packet, 40.5mg testosterone/2.5g...
-
Oct 8, 2018
Murray S. Kessler, former Chief Executive Officer and President at the Lorillard Tobacco Company, appointed President, CEO and member of the Board of Directors effective immediately Proven track...
-
Oct 1, 2018
Perrigo Company plc (NYSE: PRGO; TASE) today announced that, Valeant Pharmaceuticals North America LLC, Valeant Pharmaceuticals Ireland LTD., Dow Pharmaceuticals Sciences, Inc., and Kaken...
-
Sep 28, 2018
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has settled its Hatch-Waxman litigation relating to Picato® (ingenol mebutate) gel, 0.015%, 0.05% brought by LEO Pharma Inc., LEO...